1430475-71-0

Upstream product

• 55896-93-0 ethyl 2-(chlorosulfonyl)acetate 
• 371-40-4 4-fluoroaniline 

Downstream Products

• 1430475-76-5 1-(1H-benzo[d]imidazol-2-yl)-N-(4-fluorophenyl)-2-(4-nitrophenyl)ethenesulfonamide 
• 1430475-77-6 C₂₁H₁₄FN₃O₅S 
• 1430475-78-7 methyl 4-(2-(1H-benzo[d]imidazol-2-yl)-2-(N-(4-fluorophenyl)sulfamoyl)vinyl)benzoate 
• 1430475-79-8 ethyl 2-(4-(2-(1H-benzo[d]imidazol-2-yl)-2-(N-(4-fluorophenyl)sulfamoyl)vinyl)-2-methoxyphenoxy)acetate 
• 1430475-80-1 C₂₆H₂₃FN₂O₇S 
• 1430475-81-2 1-(1H-benzo[d]imidazol-2-yl)-N-(4-fluorophenyl)-2-(4-hydroxy-3-methoxyphenyl)ethenesulfonamide 
• 1430475-83-4 2-(4-aminophenyl)-1-(1H-benzo[d]imidazol-2-yl)-N-(4-fluorophenyl)ethanesulfonamide 
• 1430475-84-5 C₂₁H₁₈FN₃O₃S 
• 1430475-85-6 methyl 4-(2-(1H-benzo[d]imidazol-2-yl)-2-(N-(4-fluorophenyl)sulfamoyl)ethyl)benzoate 
• 1430475-86-7 ethyl 2-(4-(2-(1H-benzo[d]imidazol-2-yl)-2-(N-(4-fluorophenyl)sulfamoyl)ethyl)-2-methoxyphenoxy)acetate 
• 1430475-87-8 C₂₆H₂₅FN₂O₇S 
• 1430475-88-9 1-(1H-benzo[d]imidazol-2-yl)-N-(4-fluorophenyl)-2-(4-hydroxy-3-methoxyphenyl)ethanesulfonamide 
• 1430475-90-3 C₂₂H₁₈FN₃O₄S 
• 1430475-91-4 ethyl 2-(4-(2-(1H-benzo[d]imidazol-2-yl)-2-(N-(4-fluorophenyl)sulfamoyl)ethyl)phenylamino)-2-oxoacetate 

Relevant academic research and scientific papers

Discovery of novel type II c-Met inhibitors based on BMS-777607

Twenty-two new analogs based on the structure of BMS-777607 were designed, synthesized, and evaluated to determine their biological activities. Compounds bearing a cyclic sulfonamide or α-chloropiperidone scaffold exhibited good activity, which may provid

Design, synthesis, and biological evaluation of (E)-N-Aryl-2- arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents

A series of novel (E)-N-aryl-2-arylethenesulfonamides (6) were synthesized and evaluated for their anticancer activity. Some of the compounds in this series showed potent cytotoxicity against a wide spectrum of cancer cell-lines (IC50 values ranging from 5 to 10 nM) including all drug resistant cell-lines. Nude mice xenograft assays with compound (E)-N-(3-amino-4- methoxyphenyl)-2-(2′,4′,6′-trimethoxyphenyl)ethenesulfonamide (6t) showed dramatic reduction in tumor size, indicating their in vivo potential as anticancer agents. A preliminary drug development study with compound 6t is predicted to have increased blood-brain barrier permeability relative to many clinically used antimitotic agents. Mechanistic studies indicate that 6t and some other analogues disrupted microtubule formation, formation of mitotic spindles, and arrest of cells in mitotic phase. Compound 6t inhibited purified tubulin polymerization in vitro and in vivo and circumvented drug resistance mediated by P-glycoprotein. Compound 6t specifically competed with colchicine binding to tubulin and with similar avidity as podophylltoxin, indicating its binding site on tubulin.

Design and synthesis of 2-substituted benzoxazoles as novel PTP1B inhibitors

A series of benzoxazole compounds containing oxamic acid were synthesized and screened for the PTP1B inhibition. Compound 31d showed best biochemical potency (Ki) of 6.7 μM. Structure-activity relationship were explained with the help of molecular modeling approach.